AbCellera Biologics (ABCL) Competitors $6.10 +0.48 (+8.54%) Closing price 04:00 PM EasternExtended Trading$6.12 +0.02 (+0.25%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. RNA, GRFS, ABVX, RYTM, CRSP, NUVL, AXSM, TGTX, LEGN, and MTSRShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Avidity Biosciences (RNA), Grifols (GRFS), Abivax (ABVX), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Legend Biotech (LEGN), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. Its Competitors Avidity Biosciences Grifols Abivax Rhythm Pharmaceuticals CRISPR Therapeutics Nuvalent Axsome Therapeutics TG Therapeutics Legend Biotech Metsera Avidity Biosciences (NASDAQ:RNA) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Is RNA or ABCL more profitable? AbCellera Biologics has a net margin of -511.88% compared to Avidity Biosciences' net margin of -4,247.77%. AbCellera Biologics' return on equity of -16.17% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,247.77% -33.45% -30.22% AbCellera Biologics -511.88%-16.17%-12.24% Do institutionals & insiders hold more shares of RNA or ABCL? 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, RNA or ABCL? Avidity Biosciences has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Do analysts prefer RNA or ABCL? Avidity Biosciences presently has a consensus price target of $68.32, suggesting a potential upside of 35.36%. AbCellera Biologics has a consensus price target of $8.00, suggesting a potential upside of 31.15%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Avidity Biosciences is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 1 Sell rating(s) 0 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.95AbCellera Biologics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has stronger earnings and valuation, RNA or ABCL? AbCellera Biologics has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.73M686.34-$322.30M-$3.56-14.18AbCellera Biologics$28.83M63.23-$162.86M-$0.55-11.09 Does the media refer more to RNA or ABCL? In the previous week, Avidity Biosciences had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Avidity Biosciences and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.53 beat Avidity Biosciences' score of 0.37 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAbCellera Biologics beats Avidity Biosciences on 10 of the 16 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82B$3.39B$6.04B$10.49BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-11.0922.9085.1927.32Price / Sales63.23269.18516.16194.55Price / CashN/A46.9537.5761.53Price / Book1.7010.5312.426.81Net Income-$162.86M-$52.58M$3.32B$276.59M7 Day Performance-1.13%1.06%0.80%0.15%1 Month Performance40.23%16.05%10.52%8.17%1 Year Performance138.28%18.41%76.14%35.50% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.2514 of 5 stars$6.10+8.5%$8.00+31.1%+123.0%$1.82B$28.83M-11.09500RNAAvidity Biosciences1.9826 of 5 stars$46.18-1.7%$68.32+47.9%+3.0%$6.74B$10.73M-12.97190GRFSGrifols3.7631 of 5 stars$9.61-3.4%$10.30+7.2%+11.7%$6.61B$7.45B8.2123,822Positive NewsABVXAbivax2.8515 of 5 stars$86.67+3.3%$102.14+17.9%+925.4%$6.55BN/A0.0061Analyst ForecastHigh Trading VolumeRYTMRhythm Pharmaceuticals3.0512 of 5 stars$97.86-1.2%$106.64+9.0%+109.4%$6.50B$130.13M-32.51140CRSPCRISPR Therapeutics1.5498 of 5 stars$70.19+3.6%$71.50+1.9%+45.1%$6.38B$37.31M-12.93460Analyst ForecastNUVLNuvalent2.9372 of 5 stars$83.85-0.4%$118.89+41.8%-18.0%$6.05BN/A-17.1140Analyst ForecastAXSMAxsome Therapeutics4.688 of 5 stars$119.94-0.3%$177.93+48.4%+44.6%$5.99B$385.69M-23.66380Analyst RevisionTGTXTG Therapeutics4.4174 of 5 stars$36.76+0.1%$49.00+33.3%+49.5%$5.83B$329M99.35290Positive NewsLEGNLegend Biotech2.6379 of 5 stars$31.44-1.9%$74.22+136.1%-33.1%$5.80B$627.24M-35.732,609News CoverageMTSRMetseraN/A$52.50+1.2%$55.75+6.2%N/A$5.52BN/A0.0081 Related Companies and Tools Related Companies Avidity Biosciences Competitors Grifols Competitors Abivax Competitors Rhythm Pharmaceuticals Competitors CRISPR Therapeutics Competitors Nuvalent Competitors Axsome Therapeutics Competitors TG Therapeutics Competitors Legend Biotech Competitors Metsera Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
